Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

70.70CHF
9 Dec 2016
Change (% chg)

CHF1.30 (+1.87%)
Prev Close
CHF69.40
Open
CHF69.90
Day's High
CHF71.35
Day's Low
CHF69.65
Volume
41,397
Avg. Vol
45,285
52-wk High
CHF100.50
52-wk Low
CHF58.80

Select another date:

Tue, Nov 15 2016

BRIEF-Basilea antifungal Cresemba (isavuconazole) launched in France

* Says basilea's antifungal cresemba (isavuconazole) launched in france Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

BRIEF-MedCap unit to distribute Basilea's products in Scandinavia

* Says its unit Unimedic Pharma AB has entered into licensing and distribution agreement with Basilea Pharmaceutica Ltd

BRIEF-Basilea announces distribution agreement with Unimedic for Cresemba and Zevtera in Nordic Countries

* Announces distribution agreement with unimedic for Cresemba (isavuconazole) and Zevtera (ceftobiprole) in Nordic Countries Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea announces partnership for antifungal isavuconazole in Japan

* Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma

BRIEF-Basilea: supply, distribution and license agreement with GBT

* Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA (isavuconazole) and Zevtera (ceftobiprole) in Latin America

BRIEF-Basilea Pharmaceutica: phase 1/2a clinical study with oncology drug candidate

* Starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica: distribution agreement with Hikma for Cresemba in MENA region

for Cresemba (isavuconazole) in the MENA region Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica H1 net loss narrows to CHF 27.9 million

* Contract revenue in first half-year of 2016 amounted to 27.8 million Swiss francs ($28.50 million) (H1 2015: 24.4 million francs)

BRIEF-Basilea Pharmaceutica: CRESEMBA (isavuconazole) launched in Italy

* Basilea's antifungal CRESEMBA (isavuconazole) launched in Italy Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: